Physician profile
Robert M Simonds
NPI 1952806317
$1,174.32
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $50.85 · 2021: $350 · 2022: $76.47 · 2023: $51.25 · 2024: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.38 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.21 | 2019-2024 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $268.67 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $225.01 | 2019-2021 | |
| Incyte Corporation | $75.90 | 2021-2024 | Opzelura |
| Genzyme Corporation | $58.64 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $50.85 | 2020 | |
| Lilly USA, LLC | $38.47 | 2021-2024 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $26.48 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $25.86 | 2024 | |
| Amgen INC. | $13.23 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Simonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.